Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...

Australian researchers have made a breakthrough in improving the cure rate for the most common form of breast cancer. An ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...